Cytokines such as TNF-α, IL-17, and IL-23 drive inflammation in HS patients, with COVID-19 infection potentially enhancing this response through increased IL-1β production, IL-17 activation, and inflammasome activation [6,7,8]. This evidence concerns the gene IL17A and histiocytic sarcoma.